Post
Signal: AbbVie ends multi-million dollar cancer drug deal with I-Mab
Biopharma giant AbbVie has announced it intends to terminate its cancer drug deal with I-Mab, the creators of lemzoparlimab. The …
China’s NMPA approves Henlius’ oesophageal cancer therapy
China’s National Medical Products Administration (NMPA) has granted approval for Shanghai-based Henlius Biotech’s Hansizhuang (serplulimab injection) for use in PD-L1 …
Valneva receives JE vaccine supply contract from US DoD
Valneva has received a contract from the US Department of Defense (DoD) for the delivery of its Japanese encephalitis (JE) …
Merck and ICR enter renewed cancer drug discovery partnership
Merck KGaA (Merck) and the UK's Institute of Cancer Research (ICR) have entered a renewed strategic collaboration to discover and develop new …
Boehringer and Lilly gain FDA approval for kidney disease therapy
Boehringer Ingelheim and Eli Lilly and Company have received approval from the US Food and Drug Administration (FDA) for Jardiance …
FDA clears Krystal Biotech’s IND for Type 1 AATD treatment KB408
The US Food and Drug Administration has approved Krystal Biotech’s Investigational New Drug (IND) for a Phase I clinical trial …
Jazz Pharma’s Enrylaze wins European approval for AML and LBL
The European Commission (EC) has approved Enrylaze (recombinant Erwinia asparaginase or crisantaspase) as an add-on therapy with chemotherapy for treating …
Over half of world’s population not covered by essential healthcare services
The World Health Organization (WHO) and the World Bank have published the 2023 Universal Health Coverage (UHC) Global Monitoring Report, …
Alvotech’s AVT05 in Phase III rheumatoid arthritis study, as the sole candidate
The patent for Janssen’s second-generation, tumour necrosis factor-alpha (TNF)-a inhibitor Simponi (golimumab), is scheduled to expire in 2024 and in …
JURA Bio and Syena partner to develop TCR-based therapies
JURA Bio has entered a research collaboration with Replay cell therapy product company Syena for the development of T cell …
Signal: CMR Surgical Raises $165m to continue development of surgical robot
Cambridge, UK-based CMR Surgical has raised $165m in funding to continue the development of its Versius surgical robot. This latest …
Yale and Transcend wins US DoD grant for PTSD therapy
The US Department of Defense has awarded a collaborative grant to Transcend Therapeutics and Yale University (US). The grant is to …
Novo Holdings acquires biopharma company Paratek for $462m
Novo Holdings has concluded the acquisition of all outstanding shares of commercial-stage biopharmaceutical company Paratek Pharmaceuticals for nearly $462m (€433.67m) to bolster …
Glenmark Pharma to divest 75% stake in life sciences unit for $680m
Glenmark Pharmaceuticals has signed a definitive agreement for the divestiture of a 75% stake in its division, Glenmark Life Sciences (GLS), to …
Debiopharm, SunRock sign agreement for cancer ADCs
Debiopharm and SunRock Biopharma have signed an exclusive option and licence agreement to advance the development of specifically targeted antibody …